Similarly, when adjustments were made for gender, tumor stage, KRAS mutation, and EGFR mutation in the validation cohort, the results of the NRG signature remained significant (HR = 2.026, 95% CI = 1.371–2.993, P < 0.001) (Table 1). This evidence concerns the gene EGFR and neoplasm.